All In Biotech

Drug Trial Radar · NCT04935177

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

64

Actual

Start

Oct 14, 2021

Primary completion

Jun 20, 2025

Study completion Jun 20, 2025

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
Jun 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care

Conditions

  • Kidney Transplantation in Highly Sensitized Patients

Interventions

  • ImlifidaseDrug

    Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

  • PLEXProcedure

    PLEX is performed according to the respective site's standard procedure for desensitization.

  • IVIgDrug

    IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.

  • Anti-CD20 antibodiesDrug

    Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.

  • EculizumabDrug

    Eculizumab according to the respective site's standard procedure for desensitization.

  • Remain on wait listOther

    Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean estimated glomerular filtration rate (eGFR) at 12 monthsTime frame: 12 months after randomization

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) Hospital

    Birmingham, Alabama

  • Banner Health - University Medical Center - Phoenix

    Phoenix, Arizona

  • Mayo Clinic Phoenix

    Phoenix, Arizona

  • Keck Hospital of University of Southern California (USC)

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Sutter Health - California Pacific Medical Center

    San Francisco, California

  • University of California San Francisco (UCSF) Medical Center

    San Francisco, California

  • Georgetown Transplant Institute

    Washington D.C., District of Columbia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • John Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Minnesota Medical School

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Saint Barnabas Medical Center

    Livingston, New Jersey

  • New York University (NYU) Langone Transplant Institute, NYU Langone Health

    New York, New York

  • Columbia University

    New York, New York

  • New York-Presbyterian - Weill Cornell Medical Center

    New York, New York

  • Hospital of the University of Pennsylvania, Penn Medicine

    Philadelphia, Pennsylvania

  • Houston Methodist Hospital

    Houston, Texas

  • Methodist Hospital Specialty and Transplant

    San Antonio, Texas

  • University of Washington Medical Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.